167 related articles for article (PubMed ID: 30692274)
21. Comparison of cytology, colposcopy, HPV typing and biomarker analysis in cervical neoplasia.
Adamopoulou M; Kalkani E; Charvalos E; Avgoustidis D; Haidopoulos D; Yapijakis C
Anticancer Res; 2009 Aug; 29(8):3401-9. PubMed ID: 19661364
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of the effectiveness of BMRT-HPV for cervical cancer screening].
Duan LF; Du H; Wang C; Huang X; Qu XF; Duan XZ; Liu Y; Shi B; Zhang W; Wei LH; Belinson L; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Oct; 55(10):708-715. PubMed ID: 33120484
[No Abstract] [Full Text] [Related]
23. Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening.
Wang HY; Kim H; Park KH
Int J Infect Dis; 2019 Jan; 78():22-30. PubMed ID: 30248464
[TBL] [Abstract][Full Text] [Related]
24. Use of Multiplex Polymerase Chain Reaction for Detection of High-Risk Human Papillomavirus Genotypes in Women Attending Routine Cervical Cancer Screening in Harare.
Marembo T; Dube Mandishora R; Borok M
Intervirology; 2019; 62(2):90-95. PubMed ID: 31412350
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Performance of HPV E6/E7 mRNA and HPV DNA Assays for the Detection and Screening of Oncogenic Human Papillomavirus Infection among Woman with Cervical Lesions in China.
Wang HY; Lee D; Park S; Kim G; Kim S; Han L; Yubo R; Li Y; Park KH; Lee H
Asian Pac J Cancer Prev; 2015; 16(17):7633-40. PubMed ID: 26625774
[TBL] [Abstract][Full Text] [Related]
26. Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.
Rebolj M; Bonde J; Preisler S; Ejegod D; Rygaard C; Lynge E
PLoS One; 2016; 11(1):e0147326. PubMed ID: 26789267
[TBL] [Abstract][Full Text] [Related]
27. Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.
Liao SY; Rodgers WH; Kauderer J; Bonfiglio TA; Walker JL; Darcy KM; Carter R; Hatae M; Levine L; Spirtos NM; Stanbridge EJ
Int J Cancer; 2009 Nov; 125(10):2434-40. PubMed ID: 19670419
[TBL] [Abstract][Full Text] [Related]
28. Performance of DNA methylation-based biomarkers in the cervical cancer screening program of northern Portugal: A feasibility study.
Salta S; Maia-Moço L; Estevão-Pereira H; Sequeira JP; Vieira R; Bartosch C; Petronilho S; Monteiro P; Sousa A; Baldaque I; Rodrigues J; Sousa H; Tavares F; Henrique R; Jerónimo C
Int J Cancer; 2021 Dec; 149(11):1916-1925. PubMed ID: 34460099
[TBL] [Abstract][Full Text] [Related]
29. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
30. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
31. [A study of cervical cancer screening algorithms].
Zhao FH; Zhang WH; Pan QJ; Zhang X; Chen W; Liu B; Ma JF; Hu SY; Qiao YL
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):420-4. PubMed ID: 20819481
[TBL] [Abstract][Full Text] [Related]
32. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
Bokan T; Ivanus U; Jerman T; Takac I; Arko D
Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
[TBL] [Abstract][Full Text] [Related]
33. Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study.
Wu TJ; Smith-McCune K; Reuschenbach M; von Knebel Doeberitz M; Maloba M; Huchko MJ
BMJ Open; 2016 Sep; 6(9):e012547. PubMed ID: 27625065
[TBL] [Abstract][Full Text] [Related]
34. [Guidelines for application of molecular tests identyfying HR HPV DNA in the prevention of cervical cancer. Statement of experts from PGS (PTG) and NCLD (KIDL)].
;
Ginekol Pol; 2013 May; 84(5):395-9. PubMed ID: 23819408
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan.
Chang CL; Ho SC; Su YF; Juan YC; Huang CY; Chao AS; Hsu ZS; Chang CF; Fwu CW; Chang TC
Gynecol Oncol; 2021 May; 161(2):429-435. PubMed ID: 33757653
[TBL] [Abstract][Full Text] [Related]
36. [LC-MS/MS-based screening of new protein biomarkers for cervical precancerous lesions and cervical cancer].
Qiu F; Chen F; Liu D; Xu J; He J; Xiao J; Cao L; Huang X
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jan; 39(1):13-22. PubMed ID: 30692061
[TBL] [Abstract][Full Text] [Related]
37. Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening.
Gustavsson I; Aarnio R; Myrnäs M; Hedlund-Lindberg J; Taku O; Meiring T; Wikström I; Enroth S; Williamson AL; Olovsson M; Gyllensten U
Virol J; 2019 Aug; 16(1):107. PubMed ID: 31438976
[TBL] [Abstract][Full Text] [Related]
38. Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China's largest independent operator of pathology laboratories.
Xie F; Zhang L; Zhao D; Wu X; Wei M; Zhang X; Wu X; Fang H; Xu X; Yang M; Qi D
BMC Infect Dis; 2019 Nov; 19(1):962. PubMed ID: 31711435
[TBL] [Abstract][Full Text] [Related]
39. First-void urine: A potential biomarker source for triage of high-risk human papillomavirus infected women.
Van Keer S; Pattyn J; Tjalma WAA; Van Ostade X; Ieven M; Van Damme P; Vorsters A
Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():1-11. PubMed ID: 28689156
[TBL] [Abstract][Full Text] [Related]
40. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
